Any of the following cardiovascular events within  months prior to study entry: myocardial infarction, malignant hypertension, severe/unstable angina, symptomatic congestive heart failure, cerebral vascular accident, or transient ischemic attack
Has had known clinically significant cardiovascular disease within  months of planned start of study drug, including myocardial infarction, unstable angina, grade  or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent
History of clinically significant vascular disease, including any of the following within  months prior to day  of study drug: myocardial infarction or unstable angina, percutaneous coronary intervention, bypass grafting, ventricular arrhythmia requiring medication, stroke or transient ischemic attack, symptomatic peripheral arterial disease and/or involvement of great vessels by tumor with or without vascular grafting
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, severe or unstable angina, myocardial infarction, symptomatic congestive heart failure (defined as New York Heart Association grade II or greater), arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks) or clinically significant ventricular arrhythmias within  months prior to randomization; or significant vascular disease (e.g., aortic aneurysm, aortic dissection), symptomatic peripheral vascular disease
Has had clinically significant cardiovascular disease within  months of start of study drug, including myocardial infarction, unstable angina, grade  or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent
Clinically significant cardiovascular disease within  months prior to enrollment/randomization, including myocardial infarction, unstable angina, grade  or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication or placement of percutaneous transluminal coronary angioplasty/stent
Uncontrolled, clinically significant, symptomatic cardiovascular disease within  months before enrollment, including myocardial infarction, unstable angina, Grade  or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication.
Uncontrolled, clinically significant, symptomatic cardiovascular disease within  months before enrollment, including myocardial infarction, unstable angina, Grade  or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication.
Patients with clinically significant cardiovascular or cerebrovascular disease:\r\n* History of cerebrovascular accident or transient ischemic attack within past  months from registration\r\n* Myocardial infarction, coronary artery bypass grafting (CABG) or unstable angina within the past  months from registration\r\n* New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past  months from registration\r\n* Clinically significant peripheral vascular disease within past  months from registration
Clinically significant cardiovascular disease within  months prior to enrollment/randomization, including myocardial infarction, unstable angina, grade  or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication or placement of percutaneous transluminal coronary angioplasty/stent